July 12, 2022
  • The Virtual Case-Based Roundtable Meetings are a collaborative, small-group meeting designed around case-based clinical profiles and peer-dialogue led by an expert physician. These sessions offer practicing oncologists the perfect opportunity to sharpen their skills and expertise in treatment strategies. Attendees are paid $500 of compensation by Healthcare Research Analytics® for their attendance, participation & completion of the post-event HRA survey.
  • MOASC’s Lung Cancer Webinar Series presents Adjuvant Therapy in Non-Small Cell Lung Cancer on July 27 at 6:00pm-PDT.
  • FOTIVDA®(tivozanib), Clinical Webinar, August 25 at 5:30pm. Efficacy, Safety, and Use for Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma (rrRCC) Following 2 or More Prior Systemic Therapies.
  • MOASC’s Spotlight On Clinical Oncology, Saturday, August 27, 2022, Hyatt Huntington Beach, 1:00pm to 7:00pm-PDT. This Activity is approved for AMA PRA Category 1 Credits™
  • A CMA bill to reduce prior authorization red tape has passed out of the Assembly Health Committee. SB250 will allow physicians to spend less time on paperwork and billing and will allow patients to get the care they need without unnecessary delays.
  • California law prohibits prior authorization for biomarker testing, effective July 1, 2022.
  • Fight provider burnout by fostering workplace friendships. Supported by the California Improvement Network, a community of health care organizations promote ideas for better care delivery.
  • Healthcare workers in Los Angeles just got a raise. Los Angeles Mayor Eric Garcetti signed an ordinance July 8 that sets a $25-an-hour minimum wage for healthcare workers in the city.
  • A 4.42% proposed cut to the Medicare conversion factor for calendar year 2023, from $34.61 to $33.08, has been released by CMS. There are additional cuts proposed to oncology, imaging, and radiation.
  • Discarded amounts of certain single-dose drugs payable under Part B is one of the topics to be discussed tomorrow, Wednesday, July 13at the CMS Physicians, Nurses & Allied Health Professionals Open Door, 11:00am – 12:00pm Pacific Time (PT). Dial 15 minutes prior to start of meeting at 1-888-455-1397 & Conference Passcode: 5109694.

  • The Enhancing Oncology Model is open for applications, including from at-home cancer care providers, through Sept. 30. The voluntary payment model for cancer care that allows them to receive retrospective payments for performance on quality and savings if they assume financial risk for patient care on the front end.
  • Join CMS Administrator, Chiquita Brooks-LaSure, who will provide an update on CMS’ accomplishments and how cross-cutting initiatives are advancing CMS’ Strategic Plan.
  • Health insurance companies and self-insured employer plans must disclose how much they pay for nearly every health care service. https://khn.org/news/article/health-insurers-price-transparency-public-rates-costs/
  • Get Ready For Your Board Exam With The ASH Hematology Review Series! Starting July 11, 2022, the ASH Hematology Review Series is a free virtual learning series designed for fellows preparing to take the internal medicine hematology certification examination in November and those desiring a comprehensive update of hematology standards of care. ASH will release weekly on-demand lectures focused on classical and malignant hematology at the beginning of the week.
  • Deadline is July 15th! The Association for Clinical Oncology’s member survey on the impact of prior authorization on cancer care is in progress. 86% of state oncology societies identified prior authorization as their number one concern in the 2022 Annual Affiliate survey. Please take the survey
  • ASCO is looking for candidates to serve as an American Medical Association Current Procedural Terminology (CPT) alternate advisor. To apply or to learn more about the position, contact ASCO’s Associate Director of Coverage and Reimbursement, allison.hirschorn@asco.org
  • Join Incyte Corporation for a live webinar about myeloproliferative neoplasms (MPN). Choose from three opportunities:
  • AstraZeneca and City of Hope cordially invites you to their webinar on “HealthCare Disparities: Impacting the Barriers to Lung Cancer Screening at Federally Qualified Healthcare Centers”, on Wednesday, July 27 at 12:00pm-PST. 
  • 6th Annual School of Nursing Oncology™ Conference, July 29-30, 2022, Marriott Marquis San Diego Marina Hotel, San Diego, CA. MOASC members discounted registration. 
  • ADCETRIS® received an indication in 2018 for the treatment of adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. The following information relates to the ongoing follow-up of patients participating in the Phase 3 ECHELON-1 clinical trial. For questions regarding ADCETRIS, please visit adcetrispro.com or contact Seagen Medical Information at 1-855-4SEAGEN (1-855-473-2436) or medinfo@seagen.com.
The Medical Oncology Association of Southern California (MOASC) is a leading oncology society that advances and protects the ability of cancer patients to obtain, and the ability of the oncology physicians to provide, optimal cancer care. The material contained in the California Oncology Weekly is intended as general information for MOASC members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the California Oncology Weekly may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in California Oncology Weekly should not be used as a substitute for such advice. This publication provides a summary of regulations affecting oncology and its business practices. Reading this newsletter does not substitute for understanding regulations and verifying the validity of every claim. This information is time-sensitive and is subject to change. MOASC accepts no liability for any statements or articles herein. CPT codes are owned and trademarked by the American Medical Association. All Rights Reserved.